NEWAMSTERDAM PHARMA CO NV(NAMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NAMS NEWAMSTERDAM PHARMA CO NV

Trading 10-22 10:38:31 EDT

21.65

+0.16

+0.74%

High22.25	Low21.25	Vol79.97K
Open21.25	D1 Closing21.49	Amplitude4.65%
Mkt Cap2.59B	Tradable Cap1.96B	Total Shares119.54M
T/O1.74M	T/O Rate0.09%	Tradable Shares90.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NAMS","market":"US","secType":"STK","nameCN":"NEWAMSTERDAM PHARMA CO NV","latestPrice":21.65,"timestamp":1792679891105,"preClose":21.49,"halted":0,"volume":79965,"delay":0,"changeRate":0.007445323406235466,"floatShares":90756826,"shares":119537169,"eps":-2.144229,"marketStatus":"Trading","change":0.16,"latestTime":"10-22 10:38:31 EDT","open":21.25,"high":22.25,"low":21.25,"amount":1735690.7029499998,"amplitude":0.046533,"askPrice":21.69,"askSize":200,"bidPrice":21.61,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-2.144229,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1792699200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":21.49,"preHourTrading":{"tag":"盘前","latestPrice":21.35,"preClose":21.49,"latestTime":"09:20 EDT","volume":6870,"amount":145753.82382000002,"timestamp":1792675235401,"change":-0.14,"changeRate":-0.006515,"amplitude":0.09772},"postHourTrading":{"tag":"盘后","latestPrice":21.51,"preClose":21.49,"latestTime":"19:30 EDT","volume":21153,"amount":454594.02,"timestamp":1792625405703,"change":0.02,"changeRate":0.000931,"amplitude":0.005119},"volumeRatio":0.384309,"impliedVol":0.4318,"impliedVolPercentile":0.0677},"requestUrl":"/m/hq/s/NAMS/wiki","defaultTab":"wiki","newsList":[{"id":"2673085535","title":"NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085535","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085535?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:34","pubTimestamp":1791214446,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma's  PREVAIL phase 3 trial faces \"considerable\" risk at the interim analysis, but could prevail eventually, RBC said in a report Monday after an \"in-depth\" statistical analysis.The report said proprietary work finds risk on potentiallytoo few MACE-3 events, with 35% to 38% probability of success  for the interim results.\"Still, we see a number of potential mitigators, including thatour assumptions may be more conservative than necessary, a high PoS final analysis by end-'27, and investor sentiment which we think may be reflecting a miss already,\" the report said.The PREVAIL interim announcement in Q1 of 2027 is expected to be the largest near-term catalyst, the note said.RBC cut its price target to $42 from $50 to reflect caution on the interim analysis and the more negative investor sentiment.\"We still think risk/reward at these levels could skew favorably,and remain outperform,\" the report said.Price: 22.64, Change: -0.56, Percent Change: -2.41","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673701720","title":"RBC Cuts Price Target on NewAmsterdam Pharma to $42 From $50, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2673701720","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673701720?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:59","pubTimestamp":1791197977,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma (NAMS) has an average rating of buy and mean price target of $51.27, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672239741","title":"13D Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2672239741","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672239741?lang=en_us&edition=fundamental","pubTime":"2026-10-03 06:02","pubTimestamp":1790978520,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4214","BK4139","BK4161","CIGI","GPI","NAMS","BK4079","KNTK","TNC","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672496997","title":"NewAmsterdam Pharma CSO Johannes Jacob Pieter Kastelein Reports $1,257,659 Share Disposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2672496997","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672496997?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:31","pubTimestamp":1790973107,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma CSO Johannes Jacob Pieter Kastelein reports $1,257,659 share disposalNewAmsterdam Pharma Chief Scientific Officer Johannes Jacob Pieter Kastelein cut indirect ordinary share holdin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL9MgXcn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NewAmsterdam Pharma CSO Johannes Jacob Pieter Kastelein Reports $1,257,659 Share Disposal","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672467307","title":"NewAmsterdam Pharma Grants 71,800 Inducement Stock Options to New Hires at USD 24.16 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2672467307","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672467307?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971281,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma grants 71,800 inducement stock options to new hires at USD 24.16 per shareNewAmsterdam Pharma granted 71,800 inducement share options to seven non-executive new hires under its 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL7NVhc8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014021.USD","NDAQ","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","BCDF","IE00BN0W2T93.GBP","NAMS","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","BK4585","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671743246","title":"Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671743246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671743246?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:40","pubTimestamp":1790700010,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Invivyd (IVVD), NewAmsterdam Pharma Company (NAMS) a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-invivyd-ivvd-newamsterdam-pharma-company-nams-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-invivyd-ivvd-newamsterdam-pharma-company-nams-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XBI","LU0029874061.USD","BK4137","BK4585","BK4588","HCSG","NAMS","XLV","BK4139","IVVD","LABU","BK4539","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671121198","title":"NewAmsterdam Pharma Doses First Patient in Phase 2b Spinoza Trial of Obicetrapib in Preclinical Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2671121198","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671121198?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:04","pubTimestamp":1790683483,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma doses first patient in Phase 2b SPINOZA trial of obicetrapib in preclinical Alzheimer’s diseaseNewAmsterdam Pharma dosed the first participant in SPINOZA, a Phase 2b trial of obice","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL9S3dTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","LU2095319765.USD","NDAQ","LU0314104364.USD","NAMS","BK4585","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BQXX3F31.USD","BCDF","IE00BQXX3D17.EUR","SG9999014021.USD","BK4588","SG9999014039.USD","BK4139","LU2210149790.SGD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","IE00BN0W2W23.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669627061","title":"Menarini Group & Newamsterdam Pharma Receive European Commission Approval for Ubeslo and Evlarco","url":"https://stock-news.laohu8.com/highlight/detail?id=2669627061","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669627061?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:48","pubTimestamp":1790009307,"startTime":"0","endTime":"0","summary":"Sept 21 (Reuters) - NewAmsterdam Pharma Company N.V.::*MENARINI GROUP AND NEWAMSTERDAM PHARMA RECEIVE EUROPEAN COMMISSION APPROVAL FOR UBESLO (OBICETRAPIB MONOTHERAPY) AND EVLARCO (OBICETRAPIB PLUS EZ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nRSD5rJVRF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669162646","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669162646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669162646?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:10","pubTimestamp":1790007009,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN). NewAmster...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-newamsterdam-pharma-company-nams-and-lipocine-lpcn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-newamsterdam-pharma-company-nams-and-lipocine-lpcn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","HCSG","XBI","BK4137","LU0128526141.USD","BK4585","BK4139","LPCN","BK4581","XLV","LABU","LU0029874061.USD","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169408","title":"NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169408","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169408?lang=en_us&edition=fundamental","pubTime":"2026-09-21 22:09","pubTimestamp":1789999795,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma (NAMS) said Monday that the European Commission approved Ubeslo, an obicetrapib monotherapy, and Evlarco, an obicetrapib-ezetimibe combination, for certain patients with elevated c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322673","title":"NewAmsterdam Pharma Price Target Maintained with a $52.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322673","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322673?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NAMS/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665232230","title":"Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665232230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665232230?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:50","pubTimestamp":1788864614,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dyne Therapeutics (DYN), NewAmsterdam Pharma Company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dyne-therapeutics-dyn-newamsterdam-pharma-company-nams-and-ionis-pharmaceuticals-ions-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dyne-therapeutics-dyn-newamsterdam-pharma-company-nams-and-ionis-pharmaceuticals-ions-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XBI","LABU","BK4588","XLV","LU0128526141.USD","BK4581","LU0029874061.USD","BK4505","BK4137","IONS","HCSG","DYN","NAMS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532340","title":"Why the Dow is Being Dragged Down by a Swiss Company's Bad News","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532340?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:15","pubTimestamp":1788855300,"startTime":"0","endTime":"0","summary":"Bad news from Swiss pharmaceutical giant Novartis was weighing on the Dow on Tuesday.Investors returning from the Labor Day break could be forgiven for wondering if their eyes were deceiving them, but","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PJP","LU1983299246.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU0868494617.USD","LU1057294990.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","NAMS","BK4578","BBH","NVS","BK4534","IE00BJJMRZ35.SGD","LU0109394709.USD","LU1571399168.USD","LU2468319806.SGD","LU1061106388.HKD","BK4139","IE0002141913.USD","LU2112291526.USD","LU2242652126.USD","BK4599","LU0122379950.USD","TBXU","IBB","LU2089984988.USD","MEDX","BK4566","BK4532","BK4007","LU0070302665.USD","BK4581","LU0211331839.USD","LU1023059063.AUD","LU0320765992.SGD","IBBQ","BK4585","LU0058720904.USD","LU0208291251.USD","LU0320765489.SGD","PBE","PPH","BK4533","BK4588","LU0889565916.HKD","IE00B2B36J28.USD","BIB","SG9999001440.SGD","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665390614","title":"Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665390614","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665390614?lang=en_us&edition=fundamental","pubTime":"2026-09-07 16:11","pubTimestamp":1788768672,"startTime":"0","endTime":"0","summary":"UPDATE 2-Novartis cholesterol setback tests hopes for emerging heart disease drugsLONDON, Sept 7 (Reuters)-Shares of NovartisNOVN.Sfell more than 3% on Monday after its cholesterol drug failed in a cl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nL1N44Z05O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089284900.SGD","BBH","LU0823434583.USD","IXJ","RXL","LLY","LLII","HRTS","LU1691799644.USD","TRUH","SLN","FHLC","VHT","MEDI","AMGN","IE00BJJMRY28.SGD","OZEM","IYH","AGNG","MEDX","PBE","SGXZ99366536.SGD","TBXU","XLV","PPH","LU2750360641.GBP","NAMS","JDOC","LLYX","WDNA","IHE","THNR","CURE","LLYZ","ELIL","ELIS","TMED","FTXH","LU0097036916.USD","LU2361044865.SGD","CANC","IBB","BIB","LU1267930730.SGD","LU1571399168.USD","PJP","IBBQ","MHIP","ILDR","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664804794","title":"Newamsterdam Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664804794","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664804794?lang=en_us&edition=fundamental","pubTime":"2026-09-04 05:46","pubTimestamp":1788471990,"startTime":"0","endTime":"0","summary":"Sept 3 (Reuters) - NewAmsterdam Pharma Company N.V.::*NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 03-SEP-202620:01:00.31 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nRSD2fFVfv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664431809","title":"NewAmsterdam Pharma Grants Inducement Share Options for 52,900 Shares at $24.92 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2664431809","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664431809?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:01","pubTimestamp":1788465686,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma grants inducement share options for 52,900 shares at $24.92 eachNewAmsterdam Pharma granted inducement share options for 52,900 ordinary shares under its 2024 Inducement Plan.Optio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5W5k7c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BQXX3D17.EUR","LU0314104364.USD","NAMS","SG9999014021.USD","IE00BN0W2V16.EUR","BCDF","IE00B3QW5Z07.USD","BK4585","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","IE00BQXX3F31.USD","SG9999014013.SGD","NDAQ","SG9999014005.SGD","BK4112","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","SG9999014039.USD","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662167677","title":"NewAmsterdam Pharma to Present Phase 3 Obicetrapib Trial Data at ESC Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662167677","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662167677?lang=en_us&edition=fundamental","pubTime":"2026-08-26 20:03","pubTimestamp":1787745791,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma to present Phase 3 obicetrapib trial data at ESC Congress 2026NewAmsterdam Pharma scheduled new analyses from its Phase 3 obicetrapib program for presentation at ESC Congress 2026 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL4m3BRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BQXX3C00.GBP","BK4112","SG9999014005.SGD","BCDF","NAMS","LU2210149790.SGD","BK4588","SG9999014039.USD","BK4585","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU2095319765.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","LU0314104364.USD","IE00BQXX3F31.USD","NDAQ","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4139","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662799719","title":"NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662799719","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662799719?lang=en_us&edition=fundamental","pubTime":"2026-08-26 17:04","pubTimestamp":1787735040,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma CSO Johannes Kastelein disposes of 125,000 shares for USD 3.36 millionNewAmsterdam Pharma Chief Scientific Officer Johannes Jacob Pieter Kastelein reported a 125,000-share sale at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL1SM4sM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NewAmsterdam Pharma CSO Johannes Kastelein Disposes of 125,000 Shares for USD 3.36 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129548","title":"NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129548","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129548?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:17","pubTimestamp":1786738639,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma amends 8-K to disclose COO Douglas Kling separation, advisor agreement termsNewAmsterdam Pharma amended a July 22, 2026 Form 8-K to disclose terms of Douglas Kling’s separation and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL1bkhNf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NAMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659774126","title":"NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2659774126","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659774126?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:09","pubTimestamp":1786738191,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma appoints Robert Gunning principal accounting officerNewAmsterdam Pharma appointed Robert W. Gunning as principal accounting officer, effective Aug. 10, 2026.Gunning joined as vice ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL5bdkw9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMS","BK4139","LU1878469433.USD","BK4599","ALT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.newamsterdampharma.com","stockEarnings":[{"period":"1week","weight":0.074},{"period":"1month","weight":-0.0483},{"period":"3month","weight":-0.2966},{"period":"6month","weight":-0.2769},{"period":"1year","weight":-0.4109},{"period":"ytd","weight":-0.3874}],"compareEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":-0.0005},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0829},{"period":"1year","weight":0.1516},{"period":"ytd","weight":0.1337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.163842},{"month":2,"riseRate":0.4,"avgChangeRate":0.036652},{"month":3,"riseRate":0.5,"avgChangeRate":-0.017313},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.029307},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.010913},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.017361},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.019958},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.021568},{"month":9,"riseRate":0.666667,"avgChangeRate":0.011501},{"month":10,"riseRate":0.5,"avgChangeRate":0.036716},{"month":11,"riseRate":0.6,"avgChangeRate":0.02866},{"month":12,"riseRate":0.6,"avgChangeRate":0.126441}],"exchange":"NASDAQ","name":"NEWAMSTERDAM PHARMA CO NV","nameEN":"NEWAMSTERDAM PHARMA CO NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEWAMSTERDAM PHARMA CO NV(NAMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEWAMSTERDAM PHARMA CO NV(NAMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEWAMSTERDAM PHARMA CO NV,NAMS,NEWAMSTERDAM PHARMA CO NV股票,NEWAMSTERDAM PHARMA CO NV股票老虎,NEWAMSTERDAM PHARMA CO NV股票老虎国际,NEWAMSTERDAM PHARMA CO NV行情,NEWAMSTERDAM PHARMA CO NV股票行情,NEWAMSTERDAM PHARMA CO NV股价,NEWAMSTERDAM PHARMA CO NV股市,NEWAMSTERDAM PHARMA CO NV股票价格,NEWAMSTERDAM PHARMA CO NV股票交易,NEWAMSTERDAM PHARMA CO NV股票购买,NEWAMSTERDAM PHARMA CO NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEWAMSTERDAM PHARMA CO NV(NAMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEWAMSTERDAM PHARMA CO NV(NAMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction